Cloud DX Signs Two Contracts with US Primary Care Clinics

Cloud DX Signs Two Contracts with US Primary Care Clinics

Continued growth in US RPM as partner Maxwell Telecare signs two additional clinics in Illinois

News in Summary

  • These RPM contracts bring the total Maxwell Telecare clinics in 2022 to five
  • Addition of these two contracts brings this quarter's total number of contracts to twelve
  • Reimbursed RPM programs have the potential to impact 33% of American adults1

Cloud DX (TSXV:CDX) (OTCQB:CDXFF), Cloud DX, a leading Virtual Care platform in North America, and partner Maxwell Telecare announce two additional new contracts with US based Primary Care practices in Illinois. Under the company's Patient First™ program, the clinics will deploy Connected Health™ to control exacerbations, improve quality of life, and avoid hospital admissions, and ER visits. The participating Maxwell clinics will prescribe the kits under US codes for reimbursed Remote Patient Monitoring and Chronic Care Management, paid for by public and private health insurance. This announcement contributes to a record-setting quarter for Cloud DX bringing the total signed contracts this quarter to 12

Rajani Nair, Deployment Manager at Cloud DX, states "Maxwell Telecare understands the value of RPM and how it improves not only a clinic's return on investment but more importantly improves patient care and patient outcomes. As deployments across their network scale, the Maxwell team seamlessly integrates our Connected Health™ kit as part of their patient offerings, reimbursable in the US for RPM or Chronic Care Management. Given their ease of integration, this partnership has transitioned from establishment to scaling. We look forward to continuing to work with them"

Footnotes: 

1. Hajat, C., & Stein, E. (2018). The global burden of multiple chronic conditions: A narrative review. Preventive medicine reports, 12, 284-293. https://doi.org/10.1016/j.pmedr.2018.10.008  

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner of Medtronic Canada. 

Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

# # # 

For media inquiries please contact:
Janine Scott 
Marketing Lead 
888-543-0944 
janine.scott@CloudDX.com

For investor inquiries please contact:
Jay Bedard 
Cloud DX Investor Relations 
647-881-8418 
jay.bedard@CloudDX.com

SOURCE:Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/694570/Cloud-DX-Signs-Two-Contracts-with-US-Primary-Care-Clinics

News Provided by ACCESSWIRE via QuoteMedia

CDX:CA
The Conversation (0)
Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX chosen as Virtual Care Platform for the Ontario Paramedical Service provider, replacing existing hardware and services

Cloud DX (TSXV:CDX)(OTCQX:CDXFF) is pleased to announce a new 24-month contract with an Ontario Paramedic Service Provider enabling the client to provide Remote Patient Monitoring (RPM) across its serviceable area. Cloud DX will provide its award-winning Connected Health™ platform and support the client as it transitions from its previous remote care tools to Cloud DX's Virtual Care Platform. The client showcases how beneficial ‘Remote Care Monitoring' is for Paramedical Service providers, enabling providers to establish deeper community roots and maintain funding levels, while community members benefit from greater access to much-needed care. The client has purchased 223 Connected Health™ kits totalling ~$145,000 CAD with additional recurring fees for subscription software services. Funding for the program comes from the $82.5M Community Paramedicine for Long-Term Care program announced by the Ontario government on October 22, 2021

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Healthcare team to use Connected Health™ kits to provide dignity in care for up to 85 patients

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Announces Closing of Private Placement

Cloud DX Announces Closing of Private Placement

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 260 units (the "Units") of the Corporation at a price of $1,000 per Unit, for gross proceeds of $260,000 (the "Offering"). Each Unit is comprised of (i) a C$1,000 principal amount unsecured convertible debenture (each, a "Debenture") and (ii) 1,430 common share purchase warrants of the Corporation (each, a "Warrant"). The Debentures will mature on January 27, 2025 (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. The principal amount of the Debentures may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of C$0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant entitles the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at a price of C$0.50 per Common Share at any time prior to 4:30 p.m. (Toronto Time) on January 27, 2024

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Contract with US University Nursing School

Cloud DX Signs Contract with US University Nursing School

Cloud DX supplies Virtual Care and Remote Patient Monitoring hardware and services to educate the next generation of nurses and nurse practitioners in Oregon

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×